Post Medical Job

Do you have a permanent (full-time or part-time) opening for a high-quality medical specialist? Click Here to post More »

Post Your Resume Here

Are you a healthcare professional working long 12 -14 hour days, too many weekends and holidays, or traveling too far from home? Are you not home for dinner usually or not able to spend enough quality time with your family More »

About US

NSI Healthcare Recruiters is one of the most trusted and reliable recruitment and placement services available to medical professionals in the USA. NSI has been in business for over 29 years and has assisted many healthcare providers in locating and hiring qualified medical professionals. More »

Contact Us

Candidates: Because our posted healthcare jobs are filled quickly we ask that you contact us for the latest updates. Employers: Please post your job here for affordable placement service. More »

nsihealthcarerecruiter

We at nsihealthcarerecruiter.com pride ourselves on the highest quality, personalized-service that medical facilities and medical job applicants alike have come to expect from us. pride ourselves on the highest quality, personalized-service that medical facilities and medical job applicants alike have come to expect from us. More »

 

FDA nod for muscular dystrophy drug comes at a cost to U.S. consumers

To great applause from members of the medical community, the FDA has approved a steroid used in treating a rare form of muscular dystrophy:

The news was heralded by the Muscular Dystrophy Association of America (MDA) and others for the treatment of the debilitating disease:

However, for U.S. patients with Duchenne muscular dystrophy who have been paying about $ 1,600 a year for the drug from an U.K.-based online pharmacy, the announcement comes with sticker shock. Now that the drug will be available in the U.S., its cost is set to increase dramatically and international imports of the drug will end.

On Friday, The Wall Street Journal reported that Northbrook, Illinois-based Marathon Pharmaceuticals will begin selling the drug in the U.S. market in March under the Emflaza name with an annual price tag of $ 89,000. Patients might not shoulder the full cost, however:

Though the corticosteroid is not a cure for Duchene muscular dystrophy, it has been successful in improving muscle strength for those with access to it. In the U.S., some 12,000 males suffer from this form of the disease; most have a life expectancy into their 20s or 30s.

The MDA offers more information on its site for patients who will be making the transition from deflazacort to Emflaza:

HealthCareCommunication.com